These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34433020)

  • 21. Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer.
    Zeng D; Ye Z; Wu J; Zhou R; Fan X; Wang G; Huang Y; Wu J; Sun H; Wang M; Bin J; Liao Y; Li N; Shi M; Liao W
    Theranostics; 2020; 10(15):7002-7014. PubMed ID: 32550918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
    Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y
    Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
    Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
    Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.
    Sceneay J; Goreczny GJ; Wilson K; Morrow S; DeCristo MJ; Ubellacker JM; Qin Y; Laszewski T; Stover DG; Barrera V; Hutchinson JN; Freedman RA; Mittendorf EA; McAllister SS
    Cancer Discov; 2019 Sep; 9(9):1208-1227. PubMed ID: 31217296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence is key: Refining immunotherapy response prediction.
    Leung M; McGranahan N
    Immunity; 2023 Mar; 56(3):472-474. PubMed ID: 36921573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding genetic determinants of resistance to immune checkpoint blockers.
    Aspeslagh S; Chabanon RM; Champiat S; Postel-Vinay S
    Semin Cancer Biol; 2020 Oct; 65():123-139. PubMed ID: 31881338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine.
    Conway JR; Kofman E; Mo SS; Elmarakeby H; Van Allen E
    Genome Med; 2018 Nov; 10(1):93. PubMed ID: 30497521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomarkers associated with checkpoint inhibitors.
    Manson G; Norwood J; Marabelle A; Kohrt H; Houot R
    Ann Oncol; 2016 Jul; 27(7):1199-206. PubMed ID: 27122549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Klümper N; Wüst L; Saal J; Ralser DJ; Zarbl R; Jarczyk J; Breyer J; Sikic D; Wullich B; Bolenz C; Roghmann F; Hölzel M; Ritter M; Strieth S; Hartmann A; Erben P; Wirtz RM; Landsberg J; Dietrich D; Eckstein M
    Oncoimmunology; 2023; 12(1):2267744. PubMed ID: 37868689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.
    Hu G; Tu W; Yang L; Peng G; Yang L
    Cancer Lett; 2020 Mar; 473():148-155. PubMed ID: 31911080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.
    Chowell D; Yoo SK; Valero C; Pastore A; Krishna C; Lee M; Hoen D; Shi H; Kelly DW; Patel N; Makarov V; Ma X; Vuong L; Sabio EY; Weiss K; Kuo F; Lenz TL; Samstein RM; Riaz N; Adusumilli PS; Balachandran VP; Plitas G; Ari Hakimi A; Abdel-Wahab O; Shoushtari AN; Postow MA; Motzer RJ; Ladanyi M; Zehir A; Berger MF; Gönen M; Morris LGT; Weinhold N; Chan TA
    Nat Biotechnol; 2022 Apr; 40(4):499-506. PubMed ID: 34725502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.
    Kato S; Goodman A; Walavalkar V; Barkauskas DA; Sharabi A; Kurzrock R
    Clin Cancer Res; 2017 Aug; 23(15):4242-4250. PubMed ID: 28351930
    [No Abstract]   [Full Text] [Related]  

  • 35. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
    Zheng M
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms Controlling PD-L1 Expression in Cancer.
    Cha JH; Chan LC; Li CW; Hsu JL; Hung MC
    Mol Cell; 2019 Nov; 76(3):359-370. PubMed ID: 31668929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
    Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
    Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
    Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report.
    Roussot N; Lecuelle J; Dalens L; Truntzer C; Ghiringhelli F
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37890888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.
    Gao Y; Stein MM; Kase M; Cummings AL; Bharanikumar R; Lau D; Garon EB; Patel SP
    Cancer Immunol Immunother; 2023 Feb; 72(2):339-350. PubMed ID: 35881197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.